Gliomas With 1p/19q codeletion: A.k.a. oligodendroglioma

Gregory Cairncross, Robert Jenkins

Research output: Contribution to journalArticlepeer-review

67 Scopus citations


Today, treatment recommendations for patients with all types of gliomas are based on light microscopic evaluation of tumor tissue with no allowance for genetic variability. Oligodendrogliomas are treated in a uniform manner with, as yet, no unique therapeutic approach or targeted therapy for those harboring a codeletion of chromosomes lp and 19q. Surgical resection and radiotherapy are the standards-of-care for patients with oligodendrogliomas. Surgery improves symptoms, especially headache or seizures, and radiotherapy controls tumor growth for most patients. By extrapolation from randomized trials of glioblastoma, radiotherapy likely prolongs survival. Uncertainties persist about the timing of radiotherapy in the management of patients with low-grade oligodendrogliomas, but a superior antitumor treatment has yet to emerge. That said, the recognition that oligodendrogliomas with lp/19q loss are sensitive to current therapies and slowly growing is already influencing our management of patients with this type of glioma, spawning trials in which patients are selected by molecular signature.

Original languageEnglish (US)
Pages (from-to)352
Number of pages1
JournalCancer Journal
Issue number6
StatePublished - Nov 2008


  • 1p and 19q codeletion
  • 1p/19q LOH
  • Chromosome 1p
  • Glioma
  • Oligodendroglioma
  • Predictive biomarker
  • Prognosis
  • Therapy
  • Treatment
  • chromosome 19q
  • t(1; 19)(q10; p10)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Gliomas With 1p/19q codeletion: A.k.a. oligodendroglioma'. Together they form a unique fingerprint.

Cite this